In essence, given the high efficacy of the sGC activator runcaciguat in ZSF1 rats, as indicated by a substantial reduction in proteinuria that almost blunts the progression of proteinuria in this model, activation of sGC could be a highly effective treatment approach for CKD. The gene discussed is SGCB; the disease is chronic kidney disease.